CromaPharma 019


A state-of-the-art hyaluronic acid filling-line  

The demand for Croma-Pharma's hyaluronic acid fillers led to the construction of a new, state-of-the-art and fully automated manufacturing site which was opened in 2018.

CromaPharma 048 v2

Innovative crosslinking technology

Croma uses an innovative crosslinking technology ("macro") developed in-house to achieve a particularly stable HA matrix. In this process, a special manufacturing step first carefully aligns the hyaluronic acid (HA) chains with each other. The HA gel is then cross-linked using BDDE (a cross-linking agent) to form a three-dimensional matrix. Hyaluronic acid chains are linked together in the process, achieving higher viscosity, cohesiveness and stability. 

croma aesthetic excellence day1 050

Stability and safety thanks to automation

Croma relies on tailor-made production lines, which are characterised by their high level of automation. This minimises human influence while guaranteeing a reproducible process, consistently high quality, stability and, as a result, product safety. All production data are recorded and can be analysed in detail. During filling with the restricted area barrier system (RABS), a technology for aseptic filling is used in addition to terminal sterilisation to minimize the risk of contamination through particles and microbes.

  • 5,000 Syringes per hour
  • 2,200 m² Manufacturing site
  • 1,000 m² Clean room

If you are a healthcare professional (HCP), please log in to see specific information about our products.



* fields are required